Newcastle Clinical Trials Unit



PROACT - Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, superiority trial of enalapril to prevent Anthracycline-induced CardioToxicity

Status: Recruiting
Sponsor: South Tees NHS Hospitals Foundation Trust
Funder: NIHR RfPB
Therapeutic area: Cardiovascular and Cancer
Type of study: CTIMP

Aim: Can the ACEi Enalapril prevent anthracycline-induced cardiotoxicity in patient treated for breast cancer or Non Hodgkin lymphoma.

Primary outcome: The presence (≥14ng/L) or absence of cardiac troponin T (<14ng/L) release at any time during anthracycline treatment, and one month after the last dose of anthracycline.

Clinical Phase: III
Population: Adults
Design: RCT
Setting: Secondary Care
Planned Sample Size: 170